P/E ratio for Quest Diagnostics (DGX)
P/E ratio as of June 2025 (TTM): 22.4
According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.422. At the end of 2024 the company had a P/E ratio of 19.4.
P/E ratio history for Quest Diagnostics from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 19.4 | 6.74% |
| 2023 | 18.2 | -6.41% |
| 2022 | 19.4 | 78.04% |
| 2021 | 10.9 | -3.03% |
| 2020 | 11.2 | -33.04% |
| 2019 | 16.8 | 8.69% |
| 2018 | 15.4 | -11.69% |
| 2017 | 17.5 | -13.01% |
| 2016 | 20.1 | 39.08% |
| 2015 | 14.5 | -17.42% |
| 2014 | 17.5 | 83.14% |
| 2013 | 9.56 | -42.74% |
| 2012 | 16.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 LabCorp LH | 30.0 | 33.72% | 🇺🇸 USA |
 Psychemedics PMD | -3.75 | -116.73% | 🇺🇸 USA |
 NeoGenomics
NEO | -11.5 | -151.22% | 🇺🇸 USA |
 Enzo Biochem ENZB | -2.32 | -110.34% | 🇺🇸 USA |
 Translate Bio
TBIO.defunct | N/A | N/A | 🇺🇸 USA |
 Qiagen QGEN | 109 | 384.55% | 🇳🇱 Netherlands |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.